AstraZeneca (AZN) Share Price: What to Know Before London Market Opens on 17 November 2025
AstraZeneca closed near record highs in London on Friday, 14 November, at about 13,532p, valuing the company near £210bn. Q3 revenue rose 10% to $15.2bn, beating forecasts, but full-year guidance was unchanged. Shareholders approved a direct NYSE listing, set for February 2026. The company reported 16 positive Phase III trials and 31 regulatory approvals so far this year.